AI-generated analysis. Always verify with the original filing.
Citius Pharmaceuticals, Inc. filed an 8-K on March 10, 2026, disclosing under Item 8.01 that its majority-owned subsidiary Citius Oncology, Inc. (Nasdaq: CTOR) issued a press release announcing positive topline results. Exhibit 99.1 contains the press release dated March 10, 2026.
Event Type
Disclosure
Voluntary
Variant
8-K
Other Events. On March 10, 2026, Citius Oncology, Inc. (Nasdaq: CTOR), our majority-owned subsidiary, issued a press release announcing positive topline results
. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release, dated March 10, 2026. 104 Cover Page Interactive Data File, format